Bruno Sepodes is a Full Professor of Pharmacological Sciences at the Faculty of Pharmacy of the University of Lisbon (Portugal). He is a Pharmacist (holding a PharmD), holds a MSc in Pharmaceutical Regulatory Science, a PhD in Pharmacology and Habilitation in Pharmacology and Pharmacotherapy, all by the University of Lisbon. Bruno also holds an MPH degree from the Bloomberg School of Public Health of the Johns Hopkins University (USA). Besides being Senior Non-Clinical and Clinical Expert for INFARMED (the Portuguese National Authority for Medicines and Health Products), he became a member of the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) in 2008 and served for two mandates as Chairperson of this Committee (2012-2018). Additionally, Bruno is also member of the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP, since 2012) and of the Committee of Advanced Therapies (CAT, since 2013). In 2024 Bruno Sepodes became Chair of the Committee of Human Medicinal Products (CHMP), following two mandates as Vice-Chair of the committee (2018-2024). During 2020 Bruno became member of the EMA Emergency Task Force (ETF), representing CHMP in the efforts to deal with the challenges of COVID-19 pandemic therapeutics and vaccines, and, in 2022, with the extension of mandate of EMA and formal implementation of ETF as a constant working force of the Agency, Bruno became Co-Chair of the EMA Emergency Task Force. In 2018 he received the “EURORDIS Leadership Black Pearl Award” on Rare Diseases, attributed to an individual who has demonstrated remarkable leadership in the field of rare diseases at a European level. Bruno received 15 national and international scientific awards and was on the top 100 inspirational industry professionals of “The Medicine Maker Power List 2018”, under the category ‘Masters of Change’ for year 2018. Bruno Sepodes is author and co-author of several scientific publications in international journals and presented to national and international scientific meetings.